Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Alnylam Pharmaceuticals's price to book ratio was 15.8× on Nov 11, 2026, against 102.5× a year earlier. Over the last 5 years it ranged from 5.1× to 475.5×, with a median of 24.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 15.8× | −74.5 |
| 2025 | Dec 31, 2025 | 90.3× | −52.1 |
| 2022 | Oct 31, 2022 | 142.4× | +115.6 |
| 2021 | Dec 31, 2021 | 26.8× | +14.4 |
| 2020 | Dec 31, 2020 | 12.4× | +4.4 |
| 2019 | Dec 31, 2019 | 8.0× | +3.0 |
| 2018 | Dec 31, 2018 | 5.0× | −6.1 |
| 2017 | Dec 29, 2017 | 11.1× | +7.9 |
| 2016 | Dec 30, 2016 | 3.2× | −2.9 |
| 2015 | Dec 31, 2015 | 6.0× | −2.2 |
| 2014 | Dec 31, 2014 | 8.2× | −5.4 |
| 2013 | Dec 31, 2013 | 13.7× | +8.3 |
| 2012 | Dec 31, 2012 | 5.4× | +2.7 |
| 2011 | Dec 30, 2011 | 2.7× | +0.1 |
| 2010 | Dec 31, 2010 | 2.6× | – |
See a number that looks wrong?